## TL;DR
AI is transforming drug discovery — AlphaFold3 (2024) predicts biomolecular complex structures with atomic accuracy, while generative chemistry creates novel drug candidates de novo. The convergence of structural biology AI, molecular dynamics simulations, and generative models is compressing the 10-15 year drug development timeline toward faster, cheaper, and more targeted therapeutics.

## Core Explanation
Traditional drug discovery pipeline: (1) Target identification (disease-associated protein); (2) Hit discovery (screen millions of compounds); (3) Lead optimization (modify for potency, selectivity, ADMET); (4) Preclinical testing; (5) Clinical trials (Phase I-III). AI interventions: (A) Structure prediction — AlphaFold3 predicts 3D structures of drug targets and their interactions with candidate molecules, replacing months of X-ray crystallography; (B) Generative chemistry — diffusion models, RNNs, and graph-based generators produce novel molecules with desired properties (binding affinity, solubility, synthesizability); (C) Virtual screening — deep learning scores billions of compounds for target binding; (D) ADMET prediction — AI models forecast absorption, distribution, metabolism, excretion, and toxicity before synthesis.

## Detailed Analysis
AlphaFold3 architecture: diffusion-based model that operates on atomic coordinates directly — starting from random atom positions and iteratively denoising toward the correct structure. Unlike AF2, AF3 handles all biomolecular types (proteins, DNA, RNA, ligands, ions, covalent modifications) through a unified framework, though with reduced accuracy for RNA and antibody-antigen complexes. Isomorphic Labs (Alphabet subsidiary) is using AF3 for internal drug discovery programs and pharma partnerships. Generative models: Pocket-conditioned generation (DiffDock, TargetDiff) creates molecules that fit specific protein binding pockets. Reinforcement learning for molecular optimization (REINVENT) iteratively modifies molecules while respecting drug-likeness constraints. Key 2025 advances: equivariant diffusion models preserving molecular symmetries; multi-objective optimization balancing potency, selectivity, and pharmacokinetics. The field graduation from benchmark molecules to clinical candidates remains ongoing — Insilico Medicine's AI-discovered drug (INS018_055 for idiopathic pulmonary fibrosis) entered Phase II trials in 2023, marking the first fully AI-generated drug in clinical testing.

## Further Reading
- Isomorphic Labs Official Website
- DiffDock: Diffusion Steps, Twists, and Turns for Molecular Docking (Corso et al., 2024)
- Insilico Medicine AI-Discovered Drug Pipeline